Disappointing results from a late-stage trial in amyotrophic lateral sclerosis (ALS) have dealt a blow to Biohaven Pharmaceuticals (NYSE: BHVN).
The latest data come from the HEALEY ALS trial of verdiperstat, and show the candidate was not statistically differentiated from placebo on the main efficacy goal.
The company said that additional analyses were ongoing, and that complete study results would be presented at an upcoming scientific meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze